Li Guorong, Zhao An, Péoch Michel, Cottier Michèle, Mottet Nicolas
Department of Urology, North Hospital, CHU of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France; Inserm U1059, Saint-Etienne, France.
Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Hangzhou, China.
Urol Oncol. 2017 May;35(5):294-299. doi: 10.1016/j.urolonc.2016.12.007. Epub 2017 Jan 12.
Recent findings show that cell-free miRNAs are stable in biological fluid. Urine provides an alternative to blood serum or plasma as a potential source of tumor biomarkers. MiR-210 is proven to be overexpressed in patients with a clear cell renal cell carcinoma (ccRCC). The purpose of this pilot study was to examine the urinary cell-free miR-210 as a potential tool of liquid biopsy for ccRCC.
Overall, 75 patients with a ccRCC and 45 control subjects without a cancer were included in this study. Urine samples were centrifuged twice and the cell-free urine supernanants were stored in -80°C until use. A total of 350µl cell-free urine was used for the extraction of total RNA. The expression levels of these miRNAs were performed by using quantitative RT-PCR.
The level of urinary cell-free miR-210 was significantly higher in patients with ccRCC than in control subjects (P<0.001). The urinary cell-free miR-210 yielded the areas under the receiver operating characteristics curve of 0.76 in discriminating the patients with ccRCC from the control subjects with a sensitivity of 57.8% and a specificity of 80.0%. Moreover, the expression level of urinary cell-free miRNA-210 was significantly decreased in the patients a week after surgery (P<0.001).
Urinary cell-free miR-210 may be used as a potential tool of liquid biopsy for ccRCC diagnosis. Further studies are needed to confirm our results.
最近的研究结果表明，游离微小RNA（miRNAs）在生物体液中是稳定的。尿液可作为血清或血浆的替代物，成为肿瘤生物标志物的潜在来源。已证实miR-210在透明细胞肾细胞癌（ccRCC）患者中过表达。本初步研究的目的是检测尿液游离miR-210作为ccRCC液体活检的潜在工具。
本研究共纳入75例ccRCC患者和45例无癌症的对照受试者。尿液样本离心两次，将游离尿液上清液储存在-80°C直至使用。总共350µl游离尿液用于提取总RNA。使用定量逆转录聚合酶链反应（RT-PCR）检测这些miRNAs的表达水平。
ccRCC患者尿液中游离miR-210的水平显著高于对照受试者（P<0.001）。尿液游离miR-210在区分ccRCC患者与对照受试者时，受试者工作特征曲线下面积为0.76，灵敏度为57.8%，特异性为80.0%。此外，术后一周患者尿液中游离miRNA-210的表达水平显著降低（P<0.001）。
尿液游离miR-210可作为ccRCC诊断的潜在液体活检工具。需要进一步研究来证实我们的结果。
